Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

X
Trial Profile

A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poziotinib (Primary) ; Loperamide
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms POZITIVE20-1; ZENITH20; ZENITH20-1; ZENITH20-2; ZENITH20-4; ZENITH20-5
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 24 Jan 2024 Status changed from active, no longer recruiting to discontinued.
    • 27 Oct 2023 This trial has been completed in Belgium (global end date: 2023-04-03), according to European Clinical Trials Database.
    • 12 Sep 2023 Results assessing efficacy and safety results of poziotinib in NSCLC patients harboring HER2 exon 20 mutations who previously received at least two lines of systemic therapies, including a platinum-based regimen, presented at the 24th World Conference on Lung Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top